|
|
|
Volumn 3, Issue 2, 2012, Pages 114-115
|
|
Modulating mesothelin shedding to improve therapy
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADERBASIB;
CYTOTOXIC AGENT;
IMMUNOTOXIN SS1P;
MESOTHELIN;
TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;
UNCLASSIFIED DRUG;
ADAM PROTEIN;
BACTERIAL TOXIN;
EXOTOXIN;
GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN;
HYBRID PROTEIN;
NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;
SMALL INTERFERING RNA;
TOXA PROTEIN, PSEUDOMONAS AERUGINOSA;
TUMOR ANTIGEN;
TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;
VIRULENCE FACTOR;
APOPTOSIS;
CELL SURFACE;
CLINICAL EFFECTIVENESS;
CONCENTRATION RESPONSE;
DRUG CYTOTOXICITY;
DRUG EFFECT;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG TOLERABILITY;
EDITORIAL;
HUMAN;
LUNG CANCER;
MESOTHELIOMA;
MOLECULAR DYNAMICS;
MOLECULARLY TARGETED THERAPY;
OVARY CANCER;
PANCREAS CANCER;
PROTEIN BINDING;
PROTEIN EXPRESSION;
PROTEIN TARGETING;
GENETICS;
IMMUNOLOGY;
IMMUNOTHERAPY;
METABOLISM;
METHODOLOGY;
RNA INTERFERENCE;
TUMOR CELL LINE;
ADAM PROTEINS;
ADP RIBOSE TRANSFERASES;
ANTIGENS, NEOPLASM;
BACTERIAL TOXINS;
CELL LINE, TUMOR;
EXOTOXINS;
GPI-LINKED PROTEINS;
HUMANS;
IMMUNOTHERAPY;
MESOTHELIOMA;
MOLECULAR TARGETED THERAPY;
RECOMBINANT FUSION PROTEINS;
RNA INTERFERENCE;
RNA, SMALL INTERFERING;
VIRULENCE FACTORS;
|
|
EID: 84863806057
PISSN: None
EISSN: 19492553
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (11)
|
|
References (8)
|
